不知道ER(-)/PR(+)乳腺癌是否是一种独立的乳腺癌亚型，它与其他亚型有何不同，以及它在治疗和预后方面的意义。本研究比较了ER(-)/PR(+)乳腺癌与其他亚型，以更好地了解ER(-)/PR(+)乳腺癌的生物特征和预后，指导临床治疗并建立理论基础。我们对美国国家肿瘤人群流行病学数据库中诊断为乳腺癌的患者数据进行了回顾性分析。将ER(-)/PR(+)乳腺癌的临床病理特征，包括年龄、肿瘤大小、淋巴结状态、HER-2状态、病理类型和组织学分级，与其他类型的乳腺癌进行了比较。基于影响预后的独立风险因素，建立了风险评分系统以预测患者的预后，并创建了一个预测患者生存率的模型。利用受试者工作特征曲线（ROC曲线）和校准曲线评估模型的预测性能。T3-4级别、淋巴结阳性、HER-2阳性、浸润非特殊病理类型和G3级别在ER(-)/PR(+)乳腺癌中的比例明显高于ER(+)/PR(+)乳腺癌（p <0.001）。ER(-)/PR(+)与ER(-)/PR(-)类型的生物活性相似。ER(-)/PR(+)/HER-2(+)患者的预后优于ER(-)/PR(+) HER-2(-)患者（p<0.05）。ER(-)/PR(+)乳腺癌的预后与年龄、HER-2状态和T分期密切相关。ER(-)/PR(+)乳腺癌更类似于ER(-)/PR(-)乳腺癌，具有早发年龄、高比例的浸润非特殊类型、高组织学分级和高HER-2阳性率。是否HER-2阳性能改善ER(-)/PR(+)乳腺癌的预后值得进一步探讨。我们开发的风险评分系统能够有效区分高风险和低风险患者。我们创建的预测模型的一致性指数为0.736，并且校准曲线显示出预测结果与观察结果之间的良好一致性。 ©2023 Wang and Xue.

It is unknown whether ER(-)/PR(+) breast cancer is an independent breast cancer subtype, how it differs from other subtypes, and what its significance is regarding treatment and prognosis. This study compared ER(-)/PR(+) breast cancer with other subtypes to better understand the biological characteristics and prognosis of ER(-)/PR(+) breast cancer, to guide clinical treatment and establish a theoretical foundation.We retrospectively analyzed data for patients diagnosed with breast cancer in the Surveillance, Epidemiology, and End Results (SEER) database. The clinicopathological characteristics of ER(-)/PR(+) breast cancer, including age, tumor size, lymph node status, HER-2 status, pathological type and histological grade, were compared with other types of breast cancer. A risk scoring system was developed based on independent risk factors influencing prognosis to predict the patient's prognosis, and a nomogram model was created to predict the patient's survival rate. Receiver operating characteristic curve (ROC) and calibration curve was used to evaluate the predictive performance of the nomogram.The rates of T3-4, lymph node positivity, HER-2 positivity, infiltrating non-special pathological type, and G3 were significantly higher in ER(-)/PR(+) than in ER(+)/PR(+) cancer (p <0.001). ER(-)/PR(+) was similar to biological activity of ER(-)/PR(-) type. ER(-)/PR(+)/HER-2(+) patients had a better survival prognosis than ER(-)/PR(+) HER-2(-) patients (p<0.05). The prognosis of ER-/PR+ breast cancer was significantly associated with age, HER-2 status, and T stage.ER(-)/PR(+) breast cancer is more similar to ER(-)/PR(-) breast cancer than other breast cancer subtypes, with an early age of onset, a high proportion of infiltrating non-special types, a high histological grade, and a high HER-2 positivity rate. Whether HER-2 positivity can improve the prognosis of ER(-)/PR(+)breast cancer is worth further discussion. The risk scoring system we developed can effectively distinguish between high-risk and low-risk patients. The nomogram we created had a concordance index of 0.736, and the calibration curve showed good agreement between the predicted and observed outcomes.Copyright © 2023 Wang and Xue.